Research Suggests ExThera Medical’s Seraph® 100 Know-how Can Scale back the Unfold of Most cancers Cells
MARTINEZ, Calif., July 18, 2024–(BUSINESS WIRE)–In a groundbreaking development of a novel most cancers remedy, researchers have efficiently deployed Seraph® 100 blood filtration media to exhibit elimination of Circulating Tumor Cells (CTCs) from the blood of sufferers affected by superior pancreatic most cancers. The printed outcomes are foundational for ExThera Medical’s progressive circulating tumor cell lowering gadget, the ONCObind™ Process Hemoperfusion Filter (ONCObind™), to pave the best way for improved longevity and higher outcomes by lowering or eliminating most cancers metastasis. ONCObind™ makes use of the Seraph® 100 filtration media to filter circulating tumor cells from the blood.
Many cancers grow to be lethal once they unfold from their unique web site to different elements of the physique. CTCs, which journey via the bloodstream, play a crucial function in metastatic most cancers. By eradicating these cells, ExThera Medical’s ONCObind affords a promising method to interrupting this unfold, for longer affected person survival.
The hemoperfusion media demonstrated important discount of circulating tumor cells in affected person blood samples. Authors of the paper additional advised that blood purification utilizing Seraph® 100 media could also be thought of a pioneering novel remedy for PDAC, both alone or together with present therapies. Moreover, they asserted that the outcomes of this research can also be related for establishing remedy procedures for different cancers, as they postulated that lowering metastatic potential of the illness could enhance survival.
“By eradicating CTCs, we will doubtlessly interrupt the metastatic course of and enhance affected person outcomes,” based on the lead researcher on the research, Dr. Peter Kuhn, PhD, Founding Director of the USC Michelson Convergent Science Institute of Most cancers, and coauthor of the publication. “This gadget represents a chance to considerably enhance the take care of sufferers with pancreatic most cancers and is doubtlessly relevant to different types of most cancers.”
Within the research, blood samples of sufferers with pancreatic ductal adenocarcinoma (PDAC) underwent in vitro blood filtration utilizing the Seraph® 100 media. The outcomes confirmed a major discount in CTCs, suggesting an oncology centered product may very well be used as a therapeutic software both alone or along with different most cancers remedies comparable to chemotherapy and radiation.
“The potential of this gadget to increase and enhance the lives of most cancers sufferers is immense,” mentioned Erin Borger, CEO of ExThera Medical. “Researchers noticed on common a 94% discount in circulating tumor cells with a single use of our expertise. We’re desirous to proceed our analysis and see the influence it will probably have on affected person care.”
The outcomes of the research have been printed in Nature’s BJC Studies.
About ExThera Medical Company
ExThera Medical Company develops and commercializes extracorporeal blood filtration units, together with the Seraph® 100 MicroBind® Affinity Blood Filter for eradicating a broad vary of pathogens from the bloodstream of sufferers. Seraph® 100 can be utilized in hospitals, clinics, on battlefields and in different austere environments to handle nosocomial and community-acquired infections in addition to these brought on by battlefield wounds, pandemics, and organic warfare brokers. ExThera Medical’s extracorporeal merchandise have demonstrated life-saving capabilities in a variety of critically in poor health sufferers affected by sepsis, COVID-19, and lots of different extreme bloodstream infections. With a rising physique of end result and well being financial proof from unbiased scientific research, success within the DARPA Dialysis-Like Therapeutics program, and from profitable scientific use within the US, the EU, and the Center East, the corporate is nicely positioned to serve healthcare professionals and sufferers alike. The Seraph® 100 attained CE Mark and is commercially out there within the EU below a broad Indication For Use. The Seraph® 100 has FDA Emergency Use Authorization (EUA) for remedy of COVID-19 within the USA.
For extra info, go to the corporate’s web site at www.extheramedical.com.
About Seraph® 100 and the ONCObind Process
As a affected person’s blood flows via the Seraph® 100 filter, it passes via a mattress of small beads with receptors that mimic the receptors on human cells that pathogens goal once they invade the physique. Many dangerous substances are rapidly captured and adsorbed onto the floor of the beads and are thereby subtracted from the bloodstream. Seraph® provides nothing to the bloodstream. It targets the pathogens that trigger the an infection, whereas it additionally binds and removes dangerous substances generated by the pathogen and by the physique’s response to the an infection. Seraph’s proprietary adsorption media (the beads) represent a versatile platform that makes use of immobilized (chemically bonded) heparin for its well-established blood compatibility and its distinctive capacity to bind circulating tumor cells, micro organism, viruses, fungi, and vital sepsis mediators reported to contribute to organ failure throughout sepsis.
ExThera Medical is presently growing the ONCObind™ Process Hemoperfusion Filter (ONCObind™) to assist most cancers remedy. ONCObind™ is a part of the identical platform expertise as Seraph® 100.
For extra information tales on Seraph® 100 and ONCObind™, click on right here.
Disclaimer
All info contained on this information launch derives from believable, dependable sources which, nevertheless, haven’t been independently examined. There is no such thing as a guarantee, affirmation or assure, and no accountability or legal responsibility is taken regarding correctness or completeness. So far as it’s allowed by the related legislation, no legal responsibility in any way is taken on for any direct or oblique loss brought on by the deployment of this information launch or its contents. This communication consists of forward-looking statements relating to occasions, tendencies and enterprise prospects which will have an effect on our future working outcomes and monetary place. Such statements are topic to dangers and uncertainties that might trigger our precise outcomes and monetary place to vary materially. The funding and/or the revenues that come up from it will probably rise or fall. A complete loss is feasible. Individuals who’re in possession of this information launch are requested to acquire info regarding potential authorized limitations and to watch them accordingly. We assume no accountability to replace or revise any forward-looking statements contained on this information launch to mirror occasions, tendencies, or circumstances after the date of this information launch. Outcomes from case research (opinions) might not be predictive of future outcomes.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20240717653834/en/
Contacts
Stephanie Connolly
media@extheramedical.com
